We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Oncology

Oncology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Colovac Device vs Diverting Loop Ileostomy: A Prospective Pooled Analysis in Rectal Cancer Surgery
General SurgeryRectal Cancer SurgeryColovac

Colovac Device vs Diverting Loop Ileostomy: A Prospective Pooled Analysis in Rectal Cancer Surgery

By MedXY|Sep 19, 2026

This pooled analysis evaluates the safety and effectiveness of the Colovac Anastomosis Protection Device compared to standard diverting loop ileostomy following low anterior resection for rectal cancer, showing comparable major complication

Molecular Stratification of Early-Stage Vulvar Squamous Cell Carcinoma: Prognostic Impact of HPV and TP53 Status
newsTP53HPV

Molecular Stratification of Early-Stage Vulvar Squamous Cell Carcinoma: Prognostic Impact of HPV and TP53 Status

By MedXY|Sep 19, 2026

This study highlights how HPV and TP53 molecular subtyping in stage I vulvar squamous cell carcinoma delineates survival outcomes and recurrence risks, supporting its role in personalized management strategies.

Proteomic and Metabolomic Insights into Cardiac Remodeling in Breast Cancer Patients Undergoing Cardiotoxic Therapy
CardiologyCardiotoxicitymetabolomics

Proteomic and Metabolomic Insights into Cardiac Remodeling in Breast Cancer Patients Undergoing Cardiotoxic Therapy

By MedXY|Sep 19, 2026

This study identifies novel proteomic and metabolomic biomarkers linked to cardiac dysfunction and remodeling in breast cancer patients treated with cardiotoxic therapies, revealing potential pathways for early detection and intervention.

Optimizing Palliative Care for Effective Hospice Transitions in Cancer Patients: Insights from Multicenter Qualitative and Quantitative Evidence
Clinical Updatescancerhospice transitions

Optimizing Palliative Care for Effective Hospice Transitions in Cancer Patients: Insights from Multicenter Qualitative and Quantitative Evidence

By MedXY|Sep 15, 2026

This review synthesizes evidence identifying critical programmatic factors, relational dynamics, and interventions enhancing hospice transitions in cancer palliative care, emphasizing collaborative oncology-palliative care relationships and

Rising Early-Onset Colorectal Cancer and Persistent Racial Disparities Despite Increased Colonoscopy Use
Gastroenterologyracial disparitiesearly-onset colorectal cancer

Rising Early-Onset Colorectal Cancer and Persistent Racial Disparities Despite Increased Colonoscopy Use

By MedXY|Sep 18, 2026

From 2017 to 2023, colonoscopy use increased notably in adults under 50. Yet, early-onset colorectal cancer rates and racial disparities, particularly among Black and Hispanic populations, worsened, highlighting that screening alone does no

Evaluating Myeloablative Treosulfan-Fludarabine Conditioning in AML: A Promising Alternative for Middle-Aged Adults
Hematology-Oncologybệnh huyết họcconditioning regimen

Evaluating Myeloablative Treosulfan-Fludarabine Conditioning in AML: A Promising Alternative for Middle-Aged Adults

By MedXY|Sep 18, 2026

A phase II trial demonstrates the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning in AML patients aged 40-65, showing high leukemia-free survival and low toxicity, supporting its use over busulfan r

Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study
Hematology-OncologyLarge B-Cell LymphomaCAR T-cell therapy

Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study

By MedXY|Sep 18, 2026

Lisocabtagene maraleucel demonstrates durable five-year survival and potential cure in relapsed/refractory large B-cell lymphoma, with manageable long-term safety, based on data from the TRANSCEND NHL 001 trial and its long-term follow-up.

NF-κB Driven Transcriptional Signatures in CAR-T Cells Predict Durable Responses in Multiple Myeloma
Hematology-Oncologysingle-cell RNA sequencingNF-κB signaling

NF-κB Driven Transcriptional Signatures in CAR-T Cells Predict Durable Responses in Multiple Myeloma

By MedXY|Sep 17, 2026

Single-cell transcriptomic profiling of ide-cel CAR-T products reveals that intrinsic NF-κB signaling in CD4 CAR-T cells correlates with durable remission in relapsed/refractory multiple myeloma, marking T-cell fitness and potential therape

Reevaluating Radioactive Iodine Therapy in T3b Differentiated Thyroid Cancer: Insights from a SEER-Based Cohort Study
Diabetes & Endocrinology放射性碘治疗differentiated thyroid cancer

Reevaluating Radioactive Iodine Therapy in T3b Differentiated Thyroid Cancer: Insights from a SEER-Based Cohort Study

By MedXY|Sep 17, 2026

This cohort study of 6,638 T3b differentiated thyroid cancer patients found no survival benefit from adjuvant radioactive iodine therapy, suggesting the need for individualized treatment strategies and prospective studies focusing on recurr

Enhancing Survivorship: Multidisciplinary Rehabilitation Improves Cardiorespiratory Fitness in Upper Gastrointestinal Cancer Surgery Patients
General Surgerycardiorespiratory fitnessmultidisciplinary rehabilitation

Enhancing Survivorship: Multidisciplinary Rehabilitation Improves Cardiorespiratory Fitness in Upper Gastrointestinal Cancer Surgery Patients

By MedXY|Sep 17, 2026

RESTORE II RCT demonstrates that a 12-week multidisciplinary rehabilitation program significantly improves cardiorespiratory fitness in survivors of upper gastrointestinal cancer surgery, supporting its integration in post-oncologic care.

Trogocytosis-Mediated CLDN18.2 Acquisition by CD8+ T Cells Impairs Anti-Tumor Immunity and Drives Pancreatic Cancer Progression
newspancreatic ductal adenocarcinomaCD8+ T cells

Trogocytosis-Mediated CLDN18.2 Acquisition by CD8+ T Cells Impairs Anti-Tumor Immunity and Drives Pancreatic Cancer Progression

By MedXY|Sep 17, 2026

This study reveals that CLDN18.2 acquired by CD8+ T cells through trogocytosis impairs their glucose metabolism and cytotoxic function, promoting pancreatic cancer progression and systemic immune senescence. Targeting this axis may enhance

ATG versus Alemtuzumab for GvHD Prophylaxis in AML Allo-HCT: Insights from the EBMT Registry
Hematology-OncologyAllogeneic Hematopoietic Cell TransplantationBệnh Graft-versus-Host

ATG versus Alemtuzumab for GvHD Prophylaxis in AML Allo-HCT: Insights from the EBMT Registry

By MedXY|Sep 17, 2026

In AML patients undergoing unrelated donor allo-HCT with intermediate-intensity conditioning, ATG-based GvHD prophylaxis demonstrated better overall and leukemia-free survival and reduced relapse compared to alemtuzumab, despite higher acut

Comparing CHOP and CHOEP/EPOCH Regimens in Aggressive Adult T-Cell Leukemia/Lymphoma: Insights from an International Cohort Study
Hematology-Oncologychemotherapysurvival outcomes

Comparing CHOP and CHOEP/EPOCH Regimens in Aggressive Adult T-Cell Leukemia/Lymphoma: Insights from an International Cohort Study

By MedXY|Sep 17, 2026

This international cohort study evaluates the effectiveness of CHOEP/EPOCH versus CHOP chemotherapy in aggressive adult T-cell leukemia/lymphoma, revealing subtype-specific survival benefits in lymphomatous ATL but inconclusive results in a

Outcomes of Laryngeal Carcinoma Treatment in Female Patients: A Multicenter Retrospective Analysis
newsfemale patientscancer outcomes

Outcomes of Laryngeal Carcinoma Treatment in Female Patients: A Multicenter Retrospective Analysis

By MedXY|Sep 15, 2026

This study evaluates clinical characteristics and treatment outcomes of female laryngeal cancer patients, highlighting better survival with surgical therapy compared to non-surgical approaches, and emphasizing the need for sex-specific trea

Real-World Five-Year Survival After Neoadjuvant Therapy and Surgery in Localized Pancreatic Ductal Adenocarcinoma
General Surgeryrecurrencefive-year survival

Real-World Five-Year Survival After Neoadjuvant Therapy and Surgery in Localized Pancreatic Ductal Adenocarcinoma

By MedXY|Sep 15, 2026

This study reveals that over one-third of patients with localized PDAC receiving neoadjuvant therapy and surgery achieve actual five-year survival, highlighting the impact of early systemic failure and identifying factors predicting long-te

New International Consensus: Colorectal Cancer Risk in MASLD — What Clinicians Need to Know
GastroenterologyMASLDmetabolic disease

New International Consensus: Colorectal Cancer Risk in MASLD — What Clinicians Need to Know

By MedXY|Sep 15, 2026

An international Delphi panel concludes metabolic dysfunction‑associated steatotic liver disease (MASLD) raises colorectal cancer (CRC) risk. Experts call for earlier, risk‑adapted CRC screening and integrated metabolic care to reduce CRC b

Impact of Hypercortisolism Severity on Outcomes in Adrenocortical Carcinoma with Cushing’s Syndrome
Diabetes & EndocrinologyCushing's Syndromesurvival outcomes

Impact of Hypercortisolism Severity on Outcomes in Adrenocortical Carcinoma with Cushing’s Syndrome

By MedXY|Sep 15, 2026

This study reveals that the severity of hypercortisolism in adrenocortical carcinoma patients with Cushing’s syndrome correlates with higher metastatic risk and worse survival outcomes, highlighting its role as a marker of tumor aggressiven

Mapping Liver Cancer’s Hidden Frontiers: NCACC Uncovers Rare cIgG+ Epithelial Cells Driving Tumor Invasion
Gastroenterologyliver cancerRare malignant cells

Mapping Liver Cancer’s Hidden Frontiers: NCACC Uncovers Rare cIgG+ Epithelial Cells Driving Tumor Invasion

By MedXY|Sep 15, 2026

NCACC technology identifies rare cIgG+ epithelial cells at liver cancer invasive fronts, revealing a STAT1-dependent signaling axis promoting aggressiveness and offering new therapeutic targets in liver cancer.

Germline MSH3 and MLH3 Mutations as Tumor Suppressors Elevating Colorectal Cancer Risk via Hypermutation Signature ID4
GastroenterologyDNA mismatch repairMLH3

Germline MSH3 and MLH3 Mutations as Tumor Suppressors Elevating Colorectal Cancer Risk via Hypermutation Signature ID4

By MedXY|Sep 15, 2026

Heterozygous germline mutations in MSH3 and likely MLH3 confer an increased colorectal cancer risk through somatic second hits, inducing hypermutant, microsatellite-stable tumors characterized by signature ID4 and excess somatic deletions.

Evaluating Relapse Risks and the Role of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma
General Surgery分子プロファイリングRelapse Risk

Evaluating Relapse Risks and the Role of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma

By MedXY|Sep 15, 2026

This analysis of localized appendiceal adenocarcinoma reveals low relapse rates post-resection, identifies key histopathologic and molecular relapse predictors, and finds no significant benefit from adjuvant chemotherapy, challenging conven

1 / 25
123…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles